While many have heard the headlines surrounding Johnson & Johnson (NYSE: JNJ ) and problems with its metal hip replacements, the company's subsidiary Ethicon has more than 2,000 lawsuits pending concerning a different medical device -- vaginal mesh, which is used to give support to a patient's pelvic organs in cases of pelvic organ prolapse. In this video, Motley Fool health care bureau chief Brenton Flynn tells investors how much money could be at stake here for the company, and whether this is news to care about or just noise.
Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out The Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy, and a year of free analyst updates, by clicking here now.
No comments:
Post a Comment